Franklin Resources
BCRX icon

Franklin Resources’s BioCryst Pharmaceuticals BCRX Stock Holding History

Franklin Resources’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8M Sell
480,364
-42,917
-8% -$388K ﹤0.01% 1626
2026
Q1 		$4.98M Sell
523,281
-46,908
-8% -$364K ﹤0.01% 1522
2025
Q4 		$4.45M Buy
570,189
+104,851
+23% +$758K ﹤0.01% 1449
2025
Q3 		$3.53M Buy
465,338
+71,453
+18% +$595K ﹤0.01% 1572
2025
Q2 		$3.53M Buy
393,885
+69,490
+21% +$647K ﹤0.01% 1496
2025
Q1 		$2.43M Buy
324,395
+62,013
+24% +$500K ﹤0.01% 1616
2024
Q4 		$1.97M Sell
262,382
-1,366
-0.5% -$10.4K ﹤0.01% 1739
2024
Q3 		$1.97M Buy
263,748
+168,790
+178% +$1.28M ﹤0.01% 1751
2024
Q2 		$587K Buy
94,958
+18,031
+23% +$99.5K ﹤0.01% 2159
2024
Q1 		$391K Buy
+76,927
New +$433K ﹤0.01% 2362
2023
Q1 		– Sell
-14,414
Closed -$165K – 2318
2022
Q4 		$165K Buy
+14,414
New +$180K ﹤0.01% 2039
2016
Q2 		– Sell
-1,658,217
Closed -$4.69M – 1499
2016
Q1 		$4.69M Hold
1,658,217
– – ﹤0.01% 1112
2015
Q4 		$17.1M Buy
1,658,217
+245,400
+17% +$2.44M 0.01% 887
2015
Q3 		$16.1M Buy
1,412,817
+664,098
+89% +$8.86M 0.01% 907
2015
Q2 		$11.2M Buy
+748,719
New +$8.51M 0.01% 1014

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Franklin Resources's BCRX Position: Q2 2026 in Review

Franklin Resources reduced its BioCryst Pharmaceuticals (BCRX) stake by 8.2% in Q2 2026, selling an estimated $388K and leaving 480,364 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1626.

Franklin Resources first reported a position in BCRX in Q2 2015 and has held it in 15 quarters since. The position peaked at $17.1M in Q4 2015. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Franklin Resources held 480,364 shares of BioCryst Pharmaceuticals worth $4.8M as of Q2 2026.
  • Franklin Resources sold 42,917 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $388K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #1626 holding.
  • Franklin Resources first reported a position in BioCryst Pharmaceuticals in Q2 2015 and has held it in 15 quarters since.
  • Franklin Resources's BioCryst Pharmaceuticals position peaked at $17.1M in Q4 2015.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.